Morrisette co-authors pediatric companion to IDSA Guidance

The Infectious Diseases Society of America (IDSA) is arming healthcare practitioners in the fight against infectious disease.

Recently, some of the country’s top infectious diseases scientists and clinicians published a guidance document for antimicrobial-resistant (AMR) infections, with a specific focus on some of the more urgent and serious threats to public health.

Led by Johns Hopkins University School of Medicine physician Pranita D. Tamma, the research team published IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections in Clinical Infectious Diseases.

It was – and is – and incredibly important resource to help practitioners make optimized treatment decisions to lead patients to positive outcomes. Although treatment recommendations within this Guidance were aimed at both the adult and pediatric population, dosing recommendations were only provided for adults. Treating children, with their smaller weight and still-developing systems, requires different dosage regimens.

MUSC College of Pharmacy faculty member Taylor Morrisette and co-authors recognized the need for a companion document. He teamed up with Tamma and a number of these other infectious diseases experts to join with lead author Christine Lockowtiz of St. Louis Children’s Hospital on “Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children,” published in the Journal of the Pediatric Infectious Diseases Society Jan. 23, 2025.

“It was an honor to work with such a dedicated and inspiring group of individuals,” Morrisette said. “We hope that this document can contribute to improving health outcomes for children affected by drug-resistant infections worldwide.”